# NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

> **NCT06269640** · NA · TERMINATED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 1 (actual)

## Conditions studied

- Hypertrophic Cardiomyopathy
- Left Ventricular Septal Hypertrophy
- Mitral Valve Disease
- Aortic Valve Stenosis

## Interventions

- **DEVICE:** Septal Scoring Along Midline Endocardium

## Key facts

- **NCT ID:** NCT06269640
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-18
- **Primary completion:** 2024-12-23
- **Final completion:** 2024-12-23
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Clinical trials terminated early due to trial feasibility
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06269640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06269640, "NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06269640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*